Pano Therapeautics
1 known investors
Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.
Founders & leadership
BG
Ben GibsoninChief Executive Officer and Co-founder
KB
Ken BatchelorHead of Research & Development and Co-founder
Investors · 1
Competitors · 2
by search overlap
Palvellatx5 shared keywordsPalvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform. Its lead candidate, QTORIN rapamycin gel, is in clinical development for microcystic lymphatic malformations and other mTOR-driven dermatologic conditions.
Neurona Therapeutics4 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter>
<parameter name="founders">[]
Companies competing with Pano Therapeautics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Pano Therapeautics do?
- Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.
- Who founded Pano Therapeautics?
- Pano Therapeautics was founded by Ben Gibson, Ken Batchelor.
- Who are Pano Therapeautics's investors?
- Pano Therapeautics's investors include Western Technology Investment.